CD20+弥漫性大B细胞淋巴瘤的一线治疗：事实与未决问题。
First-line therapy of CD20+ diffuse large B-cell lymphoma: facts and open questions.
作者信息
Brusamolino Ercole
出版信息
Haematologica. 2009 Sep;94(9):1194-8. doi: 10.3324/haematol.2009.011320.
Abstract
CHOP chemotherapy, administered every 21 days, has been for years the standard therapy for advanced diffuse large B-cell lymphoma, with a long-term overall survival rate of about 40%. In this perspective article, Dr. Brusamolino discusses the recent advances in the treatment of this condition. See related paper on page 1250.
摘要
每21天进行一次的CHOP化疗多年来一直是晚期弥漫性大B细胞淋巴瘤的标准疗法，其长期总生存率约为40%。在这篇观点文章中，布鲁萨莫利诺博士讨论了这种疾病治疗方面的最新进展。见第1250页的相关论文。
相似文献
1
First-line therapy of CD20+ diffuse large B-cell lymphoma: facts and open questions.CD20+弥漫性大B细胞淋巴瘤的一线治疗：事实与未决问题。
Haematologica. 2009 Sep;94(9):1194-8. doi: 10.3324/haematol.2009.011320.
2
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.伊布替尼联合利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松（R-CHOP）治疗初治 CD20 阳性 B 细胞非霍奇金淋巴瘤患者：一项非随机、1b 期研究。
Lancet Oncol. 2014 Aug;15(9):1019-26. doi: 10.1016/S1470-2045(14)70311-0. Epub 2014 Jul 17.
3
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.含抗CD20抗体方案治疗复发或难治性慢性淋巴细胞白血病、弥漫性大B细胞淋巴瘤或滤泡性淋巴瘤患者的循证综述
Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):508-518.e14. doi: 10.1016/j.clml.2018.05.009. Epub 2018 May 23.
4
A treatment for activated B-cell-like DLBCL?一种针对活化B细胞样弥漫性大B细胞淋巴瘤的治疗方法？
Lancet Oncol. 2014 Aug;15(9):916-7. doi: 10.1016/S1470-2045(14)70327-4. Epub 2014 Jul 17.
5
6
CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options.CD20阴性弥漫性大B细胞淋巴瘤：生物学特性与新兴治疗选择
Expert Rev Hematol. 2015 Jun;8(3):343-54. doi: 10.1586/17474086.2015.1007862. Epub 2015 Feb 1.
7
Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab.来那度胺联合利妥昔单抗治疗老年复发弥漫性大B细胞淋巴瘤患者的长期无病生存
Haematologica. 2016 Sep;101(9):e385-6. doi: 10.3324/haematol.2016.147256. Epub 2016 May 31.
8
Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study.利妥昔单抗联合化疗作为中国弥漫性大B细胞淋巴瘤患者常规一线治疗方案：一项前瞻性、多中心、非干预性研究
BMC Cancer. 2016 Jul 26;16:537. doi: 10.1186/s12885-016-2523-7.
9
Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma.绝对淋巴细胞计数可预测弥漫性大B细胞淋巴瘤对化疗的反应及生存情况。
Leukemia. 2007 Oct;21(10):2227-30. doi: 10.1038/sj.leu.2404780. Epub 2007 Jun 7.
10
Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.增加利妥昔单抗（R）剂量可消除侵袭性CD20+B细胞淋巴瘤老年男性患者增加的风险并改善预后：德国淋巴瘤研究组（DSHNHL）的SEXIE-R-CHOP-14试验
Clin Adv Hematol Oncol. 2014 Aug;12(8 Suppl 16):8-9.
引用本文的文献
1
Characteristics and Results of the Management of Diffuse Large B-Cell Lymphomas: The Experience of Côte d'Ivoire.弥漫性大B细胞淋巴瘤的管理特征与结果：科特迪瓦的经验
Adv Hematol. 2012;2012:945138. doi: 10.1155/2012/945138. Epub 2012 May 28.
本文引用的文献
1
Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study.剂量密集和高剂量化疗联合利妥昔单抗及自体干细胞移植用于初治预后不良的弥漫性大B细胞淋巴瘤：一项II期多中心研究
Haematologica. 2009 Sep;94(9):1250-8. doi: 10.3324/haematol.2009.007005. Epub 2009 Jul 7.
2
CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).采用含或不含利妥昔单抗的现代化疗方案（CHOP-14）治疗的侵袭性淋巴瘤老年患者的中枢神经系统事件：德国高级别非霍奇金淋巴瘤研究组（DSHNHL）RICOVER-60试验中患者的分析
Blood. 2009 Apr 23;113(17):3896-902. doi: 10.1182/blood-2008-10-182253. Epub 2009 Jan 14.
3
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.高剂量钇-90 替伊莫单抗联合串联干细胞回输：一种用于自体造血细胞移植的门诊预处理方案。
J Clin Oncol. 2008 Nov 10;26(32):5175-82. doi: 10.1200/JCO.2008.16.8294. Epub 2008 Oct 14.
4
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.一项针对既往未经治疗的老年弥漫性大B细胞淋巴瘤患者的II期试验，该试验采用CHOP化疗方案，随后使用钇90 替伊莫单抗（泽瓦林）。
Ann Oncol. 2008 Apr;19(4):769-73. doi: 10.1093/annonc/mdm560. Epub 2008 Feb 25.
5
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).老年侵袭性CD20+B细胞淋巴瘤患者接受每两周一次的CHOP-14方案化疗6周期与8周期并联合或不联合利妥昔单抗的疗效比较：一项随机对照试验（RICOVER-60）
Lancet Oncol. 2008 Feb;9(2):105-16. doi: 10.1016/S1470-2045(08)70002-0. Epub 2008 Jan 15.
6
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.钇-90 替伊莫单抗与大剂量化疗移植方案用于非霍奇金淋巴瘤患者的 II 期试验
J Clin Oncol. 2008 Jan 1;26(1):90-5. doi: 10.1200/JCO.2007.11.9248. Epub 2007 Nov 19.
7
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation.钇-90替伊莫单抗治疗不适于自体干细胞移植的复发或难治性弥漫性大B细胞淋巴瘤患者的疗效和安全性。
Blood. 2007 Jul 1;110(1):54-8. doi: 10.1182/blood-2007-01-068056. Epub 2007 Mar 26.
8
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.对于接受R-CHOP治疗的弥漫性大B细胞淋巴瘤患者，修订后的国际预后指数（R-IPI）比标准IPI能更好地预测预后。
Blood. 2007 Mar 1;109(5):1857-61. doi: 10.1182/blood-2006-08-038257. Epub 2006 Nov 14.
9
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.利妥昔单抗联合CHOP方案与单纯CHOP方案或CHOP方案联合利妥昔单抗维持治疗老年弥漫性大B细胞淋巴瘤的比较。
J Clin Oncol. 2006 Jul 1;24(19):3121-7. doi: 10.1200/JCO.2005.05.1003. Epub 2006 Jun 5.
10
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.在预后良好的年轻弥漫性大B细胞淋巴瘤患者中，CHOP样化疗联合利妥昔单抗对比单纯CHOP样化疗：美罗华国际试验（MInT）组的一项随机对照试验
Lancet Oncol. 2006 May;7(5):379-91. doi: 10.1016/S1470-2045(06)70664-7.
Zotero 插件